Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hypertension

  Free Subscription


Articles published in J Cardiovasc Pharmacol

Retrieve available abstracts of 11 articles:
HTML format
Text format



Single Articles


    May 2018
  1. FEYZ L, Bahmany S, Daemen J, van den Meiracker AH, et al
    Therapeutic drug monitoring to assess drug adherence in assumed resistant hypertension: a comparison with directly observed therapy in three non-adherent patients.
    J Cardiovasc Pharmacol. 2018 May 23. doi: 10.1097/FJC.0000000000000602.
    PubMed     Text format     Abstract available


    February 2018
  2. ABID S, Kebe K, Houssaini A, Tomberli F, et al
    New NO Donor NCX 1443: Therapeutic Effects on Pulmonary Hypertension in the SAD Mouse Model of Sickle Cell Disease.
    J Cardiovasc Pharmacol. 2018 Feb 8. doi: 10.1097/FJC.0000000000000570.
    PubMed     Text format     Abstract available


    January 2018
  3. EKHOLM M, Jekell A, Wallen NH, Gigante B, et al
    The effects of angiotensin converting enzyme inhibition and alpha 1-adrenergic receptor blockade on inflammation and hemostasis in human hypertension.
    J Cardiovasc Pharmacol. 2018 Jan 30. doi: 10.1097/FJC.0000000000000565.
    PubMed     Text format     Abstract available


  4. PARK Y, Choi BG, Rha SW, Baek MJ, et al
    Selective ss1-Blockers Are Not Associated With New-onset Diabetes Mellitus in Hypertensive Patients.
    J Cardiovasc Pharmacol. 2018;71:38-45.
    PubMed     Text format     Abstract available


    November 2017
  5. REPAS SJ, Saad NS, Janssen PML, Elnakish MT, et al
    Memantine, an NMDA Receptor Antagonist, Prevents Thyroxin-induced Hypertension, but Not Cardiac Remodeling.
    J Cardiovasc Pharmacol. 2017;70:305-313.
    PubMed     Text format     Abstract available


    October 2017
  6. TABRIZCHI R
    Antihypertensive therapy and new on-set of diabetes mellitus: The double edge sword.
    J Cardiovasc Pharmacol. 2017 Oct 31. doi: 10.1097/FJC.0000000000000553.
    PubMed     Text format    


    June 2017
  7. HANSEN MS, Andersen A, Holmboe S, Schultz JG, et al
    Levosimendan prevents and reverts right ventricular failure in experimental pulmonary arterial hypertension.
    J Cardiovasc Pharmacol. 2017 Jun 19. doi: 10.1097/FJC.0000000000000508.
    PubMed     Text format     Abstract available


    May 2017
  8. MAGUBANE M, Michel FS, Erlwanger KH, Norton GR, et al
    Prevention of betaeta-Adrenergic-Induced Adverse Cardiac Remodelling by Gonadectomy in Male but not Female Spontaneously Hypertensive Rats.
    J Cardiovasc Pharmacol. 2017 May 30. doi: 10.1097/FJC.0000000000000506.
    PubMed     Text format     Abstract available


  9. JAIN M, Bhosale V, Tripathi D, Singh H, et al
    Antihypertensive drugs aliskiren, nebivolol, and olmesartan reduce hypertension by reducing endothelial microparticle and regulating angiogenesis.
    J Cardiovasc Pharmacol. 2017 May 9. doi: 10.1097/FJC.0000000000000503.
    PubMed     Text format     Abstract available


    March 2017
  10. IZZO JL JR, Zappe DH, Jia Y, Hafeez K, et al
    Efficacy and safety of crystalline valsartan/sacubitril (LCZ696) compared to placebo and combinations of free valsartan and sacubitril in patients with systolic hypertension: the RATIO study.
    J Cardiovasc Pharmacol. 2017 Mar 23. doi: 10.1097/FJC.0000000000000485.
    PubMed     Text format     Abstract available


    April 2016
  11. KAMIMURA D, Uchino K, Ishigami T, Hall ME, et al
    Activation of Peroxisome Proliferator-Activated Receptor gamma Prevents Development of Heart Failure with Preserved Ejection Fraction; Inhibition of Wnt-beta-catenin Signaling as a Possible Mechanism.
    J Cardiovasc Pharmacol. 2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hypertension is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: